Reabold Resources Regulatory News (RBD)

5 Dec 2006 07:03

Adventis Group PLC05 December 2006 For release 7.00am December 5th 2006 Adventis Group plc (ATG.L) The Full Service Marketing and Advertising Group Contract Gain "Merz Pharmaceuticals appoints Adventis' healthcare specialist Roundhouse HealthAd to launch new products into the UK" Adventis Group plc ("Adventis"), announces that its marketing, design andadvertising subsidiary within the healthcare sector, Roundhouse Healthad ("Roundhouse"), acquired last May, has been appointed by German-based MerzPharmaceuticals GmbH ("Merz Pharma"), to provide Advertising and Promotionalservices on the launch of two new products into the UK market next year and topromote Merz Pharma's corporate presence in the UK. A substantial contractencompasses direct to healthcare professional promotion. Roundhouse won the contract in tender against four other agencies, with a briefto introduce Merz Pharma and its corporate credentials into the UK market, andto develop launch campaigns for two new products: 1. Xeomin (botulinum neurotoxin type A) 2. Belotero (a monophasic hyaluronic acid filler). At the pitch, Roundhouse were required to demonstrate considerable versatility,familiarity and insight into this marketplace, and to consider a variety ofcommunications channels to address the many different audiences targeted in bothNHS and aesthetic dermatology/cosmetic settings. Merz Pharma, which produces ethical, consumer and dental products, acquiredDenfleet Pharma, in June 2006, an established U.K. marketing and distributioncompany, as a conduit to distribute their products in the UK. This acquisitionalso forms part of their Europe-wide strategy for expansion. Roundhouse has had a long association with Denfleet Pharma, and providedservices to Denfleet in its successful launch of Denzapine fortreatment-resistant schizophrenia. Kevin McGetrick, Managing Director of Roundhouse, commented: "Merz Pharma provided a particularly interesting and challenging brief and weare delighted to be appointed. As part of the Adventis Healthcare group, we nowhave greater resources to achieve market access to different audiences. Merzhave a sound, research-based heritage and offer particularly innovativeproducts. We will ensure these values and benefits are reflected with tailoredcommunications to the targets Merz Pharma want to reach." Charles Phillpot, CEO of Adventis, added: "I am delighted by this new win and the endorsement a large multinational grouplike Merz Pharma gives to Adventis' healthcare capabilities. The combination ofour heathcare facing subsidiaries, Roundhouse and Affiniti, gives us realcritical mass and expertise in this sector and I look forward to theircontinuing excellent development". - ENDS - Enquiries: Adventis Group plcCharles Phillpot, Chief Executive Officer Tel: 020 7034 4750 Roundhouse HealthadKevin McGetrick, Managing Director Tel: 01707 335 599 Arbuthnot SecuritiesTom Griffiths Tel: 020 7012 2000 Adventis Financial PRPeter Binns Tel: 020 7034 4760 / 07768 392 582Chris Steele Tel: 020 7034 4759 / 07979 604 687 Notes to Editors Adventis Group plc www.adventis.co.uk Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its ten operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 120 staff in London and the South East. Roundhouse Healthad www.roundhouse-healthad.com Roundhouse is a specialist creative healthcare communications company providingbespoke and innovative business solutions to healthcare companies. Roundhousehad been trading for over 10 years before its acquisition by Adventis in May2006. It has 12 staff that operate from headquarters near Hertford. Roundhousehas a strong base of blue chip pharmaceutical clients which include Baxter,Boehringer Ingelheim, Merial, Organon, Pfizer AH and Schering-Plough and nowMerz The combination of Roundhouse with Adventis' existing operations in thehealthcare sector through subsidiary, Affiniti (UK) Ltd, a leading mediaservices provider to the Healthcare sector is delivering an outstanding range ofskills and in depth understanding for clients and has placed Adventis within thetop 10 healthcare agencies in the UK. Merz Pharmaceuticals GmbH www.merz.com Merz Pharmaceuticals is the Frankfurt am Main, Germany-based subsidiary ofmultinational Group Merz. Merz Pharmaceuticals is an innovative pharmaceuticalcompany specializing in the research and marketing of drugs for the treatment ofneurological and psychiatric diseases. Merz is leading in the field ofAlzheimer's research and developed the world's first drug for the treatment ofmoderate to severe stages of Alzheimer's disease. In the neurological sector,Merz also offers drugs for the treatment of Parkinson's and depression. Another area of competence is dermatology. In this field, Merz products focus onthe treatment of scars, acne, hair loss, and fungal diseases. In the area ofmetabolic disturbances, Merz offers therapies for liver disease and lipidmetabolism disorders. As one of the leading German pharmaceutical companies with its own fundamentalresearch and development, Merz contributes to the prevention and cure of diseaseby concentrating on the development of innovative drugs. Merz Pharmaceuticals GmbH, Frankfurt am Main, announced on 9 June 2006 thepurchase of Denfleet Pharma Ltd., a UK based, privately owned pharmaceuticalcompany. Merz intends to utilise Denfleet's expertise and strong hospitalpresence, particularly in the CNS area, to create a launch pad for futureactivities in the UK. This acquisition forms part of a Europe wide strategy forexpansion. Denfleet Fact File • Founded in 1994 • Concentrates on the licensing, marketing and distribution of speciality pharmaceutical products in the areas of neurology and psychiatry. • Denfleet's main product, Denzapine (clozapine) is an atypical antipsychotic agent used in the treatment of schizophrenia and is particularly useful in patients who are resistant to other therapies. • To maximise patient safety, Denfleet Pharma set up the Denfleet Clozapine Monitoring Service (DCMS), a web based monitoring service, to ensure that all patients are effectively monitored. Before treatment with Denzapine can be initiated, patients must be enrolled with the DCMS and have regular blood samples throughout. • Employs 26 staff • Turnover in fiscal year 2005/6 was £5.2million (Eur 8.1 million) • Based in London and Elstree, Hertfordshire This information is provided by RNS The company news service from the London Stock Exchange